Exosome-Mediated Response to Cancer Therapy: Modulation of Epigenetic Machinery

被引:14
作者
Khan, Mohammad Imran [1 ,2 ]
Alsayed, Reem K. M. E. [3 ]
Choudhry, Hani [1 ,2 ]
Ahmad, Aamir [3 ]
机构
[1] King Abdulaziz Univ, Fac Sci, Biochem Dept, Jeddah 21589, Saudi Arabia
[2] King Abdulaziz Univ, Ctr Artificial Intelligence Precis Med, Jeddah 21589, Saudi Arabia
[3] Hamad Med Corp, Acad Hlth Syst, Translat Res Inst, Doha 3050, Qatar
关键词
cancer drug resistance; exosomes; miRNAs; lncRNAs; methyltransferases; TAMOXIFEN RESISTANCE; CISPLATIN RESISTANCE; DRUG-RESISTANCE; NONCODING RNAS; LUNG-CANCER; CELLS; CHEMORESISTANCE; GEMCITABINE; MECHANISMS; INVASION;
D O I
10.3390/ijms23116222
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Exosomes, the extracellular vesicles produced in the endosomal compartments, facilitate the transportation of proteins as well as nucleic acids. Epigenetic modifications are now considered important for fine-tuning the response of cancer cells to various therapies, and the acquired resistance against targeted therapies often involves dysregulated epigenetic modifications. Depending on the constitution of their cargo, exosomes can affect several epigenetic events, thus impacting post-transcriptional regulations. Thus, a role of exosomes as facilitators of epigenetic modifications has come under increased scrutiny in recent years. Exosomes can deliver methyltransferases to recipient cells and, more importantly, non-coding RNAs, particularly microRNAs (miRNAs), represent an important exosome cargo that can affect the expression of several oncogenes and tumor suppressors, with a resulting impact on cancer therapy resistance. Exosomes often harbor other non-coding RNAs, such as long non-coding RNAs and circular RNAs that support resistance. The exosome-mediated transfer of all this cargo between cancer cells and their surrounding cells, especially tumor-associated macrophages and cancer-associated fibroblasts, has a profound effect on the sensitivity of cancer cells to several chemotherapeutics. This review focuses on the exosome-induced modulation of epigenetic events with resulting impact on sensitivity of cancer cells to various therapies, such as, tamoxifen, cisplatin, gemcitabine and tyrosine kinase inhibitors. A better understanding of the mechanisms by which exosomes can modulate response to therapy in cancer cells is critical for the development of novel therapeutic strategies to target cancer drug resistance.
引用
收藏
页数:14
相关论文
共 79 条
[71]   Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210 [J].
Yang, Zhiyong ;
Zhao, Ning ;
Cui, Jing ;
Wu, Heshui ;
Xiong, Jiongxin ;
Peng, Tao .
CELLULAR ONCOLOGY, 2020, 43 (01) :123-136
[72]   Delivery of MGMT mRNA to glioma cells by reactive astrocyte-derived exosomes confers a temozolomide resistance phenotype [J].
Yu, Tianfu ;
Wang, XieFeng ;
Zhi, Tongle ;
zhang, Junxia ;
Wang, Yingyi ;
Nie, Er ;
Zhou, Fengqi ;
You, Yongping ;
Liu, Ning .
CANCER LETTERS, 2018, 433 :210-220
[73]   O6-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy [J].
Yu, Wei ;
Zhang, Lili ;
Wei, Qichun ;
Shao, Anwen .
FRONTIERS IN ONCOLOGY, 2020, 9
[74]   CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer [J].
Zhang, Haiyang ;
Deng, Ting ;
Liu, Rui ;
Ning, Tao ;
Yang, Haiou ;
Liu, Dongying ;
Zhang, Qiumo ;
Lin, Dan ;
Ge, Shaohua ;
Bai, Ming ;
Wang, Xinyi ;
Zhang, Le ;
Li, Hongli ;
Yang, Yuchong ;
Ji, Zhi ;
Wang, Hailong ;
Ying, Guoguang ;
Ba, Yi .
MOLECULAR CANCER, 2020, 19 (01)
[75]   Exosomes from Bone Marrow Microenvironment-Derived Mesenchymal Stem Cells Affect CML Cells Growth and Promote Drug Resistance to Tyrosine Kinase Inhibitors [J].
Zhang, Xiaoyan ;
Yang, Yazhi ;
Yang, Yang ;
Chen, Huijun ;
Tu, Huaijun ;
Li, Jian .
STEM CELLS INTERNATIONAL, 2020, 2020
[76]  
Zhao Y, 2021, AGING-US, V13, P18498, DOI 10.18632/aging.203298
[77]   Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells [J].
Zheng, Peiming ;
Chen, Lei ;
Yuan, Xiangliang ;
Luo, Qin ;
Liu, Yi ;
Xie, Guohua ;
Ma, Yanhui ;
Shen, Lisong .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2017, 36
[78]   Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway [J].
Zhou, Jian ;
Qu, Guimei ;
Zhang, Ge ;
Wu, Zuoren ;
Liu, Jing ;
Yang, Dawei ;
Li, Jing ;
Chang, Meijia ;
Zeng, Hengshan ;
Hu, Jie ;
Fang, Tao ;
Song, Yuanlin ;
Bai, Chunxue .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
[79]   PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway [J].
Zhou, Jian ;
Kwak, Kwang Joo ;
Wu, Zuoren ;
Yang, Dawei ;
Li, Jing ;
Chang, Meijia ;
Song, Yuanlin ;
Zeng, Hengshan ;
Lee, L. James ;
Hu, Jie ;
Bai, Chunxue .
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 47 (05) :1909-1924